Golimumab treatment provides superior treatment of rheumatoid arthritis .

This report has been verified by one or more authors of the original publication.

This study has been identified as potentially high impact. OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself. Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone. This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial